JonesResearch analyst Catherine Novack initiated coverage of Korro Bio (KRRO) with a Buy rating and $130 price target Korro is one of a growing number of biotech companies focused on RNA editing using ADAR to modify proteins in vivo, the analyst tells investors in a research note. The firm believes the company’s proof-of-concept data in alpha-1 antitrypsin deficiency will unlock opportunities in more prevalent indications, such as pain, liver disease, and cardiovascular disease.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KRRO:
- Korro Bio’s Progress and Financial Updates
- Korro Bio reports Q3 EPS ($2.26), consensus ($2.61)
- Korro Bio announces regulatory filing for initiation of KRRO-110
- Korro Bio price target raised to $105 from $95 at RBC Capital
- Korro Bio initiated with a Strong Buy at Raymond James
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
